Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates the ability to support diagnosis and monitor of the dynamics in ADD/ADHD subjects with an easy to use EEG Device.
The study will be conducted in two arms (arm I and arm II). In arm I, participants diagnosed with ADD/ADHD. In arm II, healthy participants.
The status of the participants will be evaluated with questionnaires computerized test and EEG characteristics will be collected for all study participants. .
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants diagnosed with ADD/ADHD | Experimental | EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration |
|
| Healthy participants | Experimental | EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EEG monitoring (MindWave by NeuroSky) | Device | EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset. |
| Measure | Description | Time Frame |
|---|---|---|
| Measurements of brain electrical signal in Micro volt. | Measurements of brain electrical signal in Micro volt will be quantified by an algorithm and correlated to ADHD state as evaluated by participants questionnaires, and computerized test. | 2 weeks |
Not provided
Not provided
Inclusion Criteria:
Diagnosed with ADD/ADHD based on clinical evaluation based on the questionnaires:
Exclusion Criteria:
Diagnosed with Psychotic or bipolar disorder.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yuval Bloch, MD | Shalvata Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shalvata Hospital | Hod HaSharon | Israel |
Not provided
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D008774 | Methylphenidate |
| ID | Term |
|---|---|
| D010648 | Phenylacetates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| EEG monitoring (EPOC by Emotiv) | Device | EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. |
|
| Methylphenidate | Drug | Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly. |
|
| D010880 |
| Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |